FAST™ Nanoemulsion Technology Aimed to Be a Competitive Advantage for Organigram’s Ingestible Liquid Formula.
TORONTO, August 07, 2024–(BUSINESS WIRE) –Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), a leading licensed producer of cannabis, is pleased to present the first results of its pivotal clinical pharmacokinetic (PK) study conducted on the product. Development Collaboration (PDC) on its latest innovation, nanoemulsion technology. This patent-pending technology has been documented QUICKLY™ (Fast-acting Controlled Technology), will be the first production to be sold by Organigram using the production of PDC*, a “Center of Excellence” established to focus on the development of next-generation cannabis products.
The clinical study was completed in January 2024, and the final data set was accepted and reviewed. The final report is expected to be published in October 2024.
The survey results provided early indications of technological advances, including but not limited to:
-
Faster onset compared to conventional edibles from the control group. Depending on the edible form, up to 50% faster effects of cannabis were observed.
-
Improved bioavailability of cannabinoids: reaching twice the peak cannabinoid supply compared to the control group.
-
Early indications of the longer-term effects of cannabis show promising signs for the development of future applications, according to some supporting studies.
“We are excited by the study’s findings. The patent-pending nanoemulsion technology, FAST™, promises to unlock the power of infused cannabinoids and allow consumers to more precisely direct and control their dosing experience – point of consumer pain in the edible product space. This technological advancement underscores Organigram’s commitment to customer and technology-driven innovation,” said Borna Zlamalik, SVP of Innovation and R&D.
Organigram has reviewed and is committed to raising awareness of the application of active technology, in accordance with Health Canada regulations. “As a responsible licensed producer, our goal is to fully educate customers on the effects of this technology, empowering them to enjoy a controlled and predictable experience,” added Mr. Zlamalik.
This study is believed to be one of the largest PK studies focused on recreational cannabis products used by adults. A rigorous, 19-day, eight-arm study conducted by a leading third-party clinical research organization examined cannabinoid absorption in three key product types to determine the effectiveness of the new delivery system. .
Organigram expects to sell FAST™ in the fall of 2024, starting with gummies. Production trials for these gummies are underway at Organigram’s Winnipeg facility.
“Organigram has always focused on customer-centric innovation as one of its core divisions and our commitment to the development of cutting-edge technology underscores this commitment,” said Beena Goldenberg, CEO of Organigram. . “We are confident that our investment in this technology will pave the way for our continued success in the food industry here and abroad.”
* The Product Development Collaboration (“PDC”) is a partnership between BAT and Organigram and was created to focus on the development of next-generation cannabis products.
About the Organigram
Organigram is a NASDAQ Global Select Market and TSX-listed company whose wholly-owned subsidiary Organigram Inc. is a licensed producer of cannabis, cannabis-derived products and cannabis-infused edibles in Canada.
Organigram is focused on producing high-quality cannabis for adult recreational consumers as well as developing international business partnerships to expand the Company’s global footprint. Organigram has also developed and acquired a collection of legal products used by adult recreational users, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates agricultural and manufacturing facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated food manufacturing facility in Winnipeg, Manitoba. The company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations (Canada).
Forward-Looking Information
This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “anticipates”, “estimates”, “plans”, “anticipates”, “believes” or variations of such words and phrases. or state that certain actions, events, or results “may”, “could”, “may” or “will” happen, occur or be achieved. Forward-looking information includes known and unknown risks, uncertainties and other factors that could cause actual results, events, performance or success of Organigram to differ materially from current expectations or results. future, performance or success expressed or implied by the forward-looking information provided. in this news release.
Risks, uncertainties and other factors involved in forward-looking information may cause actual events, results, performance, opportunities and possibilities to differ materially or materially from those described by such forward-looking information. include factors and risks such as management and market conditions, results of business initiatives as well as factors and risks disclosed in the Company’s most recent annual information form, management interviews and reviews and other Company documents which are periodically posted on SEDAR+ (see www.sedarplus.ca) and filed with the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.
Although the Company believes that the assumptions and data used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events they will happen at revealed times or not at all. The forward-looking information included in this news release is made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or update any such information or which is anticipated, whether as a result of new information, future events or otherwise.
Check out the source version at businesswire.com: https://www.businesswire.com/news/home/20240807039495/en/
Names
For Media inquiries:
Megan McCrae
Senior Vice President of Global Products and Corporate Affairs
megan.mccrae@organigram.ca
For Investor Relations Questions:
Max Schwartz
Director of Investor Relations
investor@organigram.ca
#Organigram #Product #Development #Partnership #Completes #Clinical #Study #Nanoemulsion #Technology